Abstract
The absorption, distribution, metabolism and elimination of the anti-epileptic drug lacosamide were determined in 10 healthy male volunteers following intravenous or oral administration in a single-center, open-label, single-dose trial. Volunteers were randomized to receive either a continuous intravenous infusion of 100 mg (40 μCi) [14C]-lacosamide administered over 60 min, or a 100 mg (40 μCi) [14C]-lacosamide dose given as an oral solution. During the infusion, total radioactivity concentrations reached peak levels at 1 h post dose followed by a decline of 71 % within 24 h. More than 97 % of radioactivity was excreted within 168 h; 96.8 % in urine and 0.3 % in feces. Following oral administration, total radioactivity concentrations increased to peak levels within 0.5 h followed by a decline of 65 % within 24 h. Approximately 94.6 % of radioactivity was excreted within 168 h after oral administration, 94.2 % by the kidneys and 0.4% in feces. A comparison of AUC values (po/iv) of unchanged lacosamide indicates a high absolute bioavailability. The metabolic profile was analyzed using pooled urine samples, and following intravenous and oral administration, respectively, a total of 38 and 34 % unchanged lacosamide, 28 and 28 % of the desmethyl metabolite and 19 and 17 % of a polar fraction were measured. Additional metabolites were identified only in small amounts (<3 %). In plasma at maximum concentration, most of the total radioactivity was found as unchanged drug after intravenous and oral dose. The plasma concentration curves of total radioactivity following intravenous and oral administration were similar.
Similar content being viewed by others
References
Beydoun A, D’Souza J, Hebert D, Doty P (2009) Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 9:33–42
Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T (2007) Lacosamide: a review of preclinical properties. CNS Drug Rev 13:21–42
Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD (2008) Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49:418–424
Cawello W, Kropeit D, Schiltmeyer B, Hammes W, Horstmann R (2004) Food does not affect the pharmacokinetics of SPM 927 (abstract). Epilepsia 45:307
Cawello W, Nickel B, Eggert-Formella A (2010) No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 50:459–471
Cawello W, Bonn R and Boekens H (2012) Bioequivalence of the intravenous and oral formulations of the anti-epileptic drug lacosamide. Pharmacology (in press)
Doty P, Rudd GD, Stoehr T, Thomas D (2007) Lacosamide. Neurotherapeutics 4:145–148
Hovinga CA (2003) SPM-927 (Schwarz Pharma). IDrugs 6:479–485
Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R (2004) Bioequivalence of short-time infusions compared to oral administration of SPM 927 (abstract). Epilepsia 45:123–124
Landmark CJ, Patsalos PN (2010) Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 10:119–140
Nickel B, Zisowsky J, Cawello W, Lovern M, Sargentini-Maier ML (2008) Population pharmacokinetics of LCM in subjects with partial-onset seizures: results from two phase III trials (abstract). J Clin Pharmacol 48:1129
UCB Pharma SA (2011) Vimpat European public assessment report (EPAR), updated 13/10/2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000863/WC500050339.pdf Accessed April 2012
Acknowledgments
This work was supported by UCB Pharma. Inverest Research (Edinburgh (clinical part) and Tranent (analytical parts), Scotland) was the contract research organization of the study. The institute conducted the clinical part of the study, the measurement of total radioactivity, analytical evaluation for identification of metabolites, and statistical evaluation of the data. Merrilee Johnstone, PhD from Prescott Medical Communications Group (Chicago, IL) as well as Azita Tofighy, PhD from UCB Pharma (Brussels, Belgium) provided writing assistance.
Conflict of interest
Willi Cawello and Hilmar Boekens are current employees of UCB Pharma. Rainer Bonn is a former employee of UCB Pharma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cawello, W., Boekens, H. & Bonn, R. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet 37, 241–248 (2012). https://doi.org/10.1007/s13318-012-0093-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-012-0093-x